Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone
This journal article was triaged for T1 - Hematologic Malignancies based on title and PubMed metadata review. It appears low priority because it addresses a more indirect biomedical question with limited evidence maturity.
This journal article was triaged for T1 - Hematologic Malignancies based on title and PubMed metadata review. It appears low priority because it addresses a more indirect biomedical question with limited evidence maturity.
What the study was
- Study design
- Journal article
- Maturity
- Exploratory
- Journal
- Future oncology (London, England)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.